Nanobiotix Stock Rises +16.92% at Midday, Driven by a Technical Rebound After Seven Sessions of Decline
French biotech company Nanobiotix sees a resurgence on Tuesday at the Paris Stock Exchange, marking a significant recovery after an extremely tumultuous week. At 13:20, the stock is up 16.92% at 15.62 euros, spurred by bargain buying amid high volatility. This technical rebound, far from trivial, comes after seven consecutive declines that resulted in a cumulative loss of over 40% in one week, presenting repositioning opportunities for some investors.
Sharp Contrast to Previous Session
Today's movement sharply contrasts with the previous session, where the stock fell 17.12% to close at 13.36 euros, marking the largest drop in the deferred settlement segment. This steep correction was part of a dark streak triggered last Friday by the announcement of a one-year delay in the initial results of the phase 3 trial, the company's main clinical program. Despite this extreme volatility over the past seven days, the outlook remains radically different over a longer horizon: in three months, Nanobiotix has gained 171.70%, and over twelve months, the stock shows a spectacular increase of 275.50%, far exceeding the CAC 40's performance of 9.81% over the same annual period. Trading volume remains moderate at 1.55% of circulating capital this Tuesday, reflecting regulated liquidity despite significant price movements. The market's reaction occurs in a context where the benchmark Paris index slightly declines by 0.07%, further highlighting the biotech's resilience after its weekly debacle. The stock's ability to rebound more than 16% in a single session illustrates remarkable volatility, with prices fluctuating at extreme levels and attracting traders looking for repositioning after the past week's massive sell-offs.
Challenging Recent Context for the Company
The recent days remain challenging for the company. Last Friday, Nanobiotix's stock fell following the announcement of a delay in the results of its major phase 3 study on squamous cell carcinomas of the head and neck. The transfer of responsibility for this trial to Johnson & Johnson, completed a year ago, significantly changes the publication schedule. According to the latest information from the American pharmaceutical giant, the interim analysis of the results will now be communicated in the first half of 2027, instead of the first half of 2026 as previously anticipated by analysts. This one-year shift is mainly explained by difficulties in patient recruitment, given the complexity of these types of tumors. The real challenge for Nanobiotix lies elsewhere: this publication expected beyond the cash horizon set by the biotech, estimated at mid-2026, places financing at the heart of concerns. Analysts from Jefferies and Stifel highlight this structural issue, while the delay in the schedule also postpones the payment of certain conditional payment milestones related to the trial. Despite these uncertainties, both research offices remain bullish on the stock, with target prices of 21 and 25 euros respectively.
Technical Indicators Show Mixed Signals
Technically, the Nanobiotix stock displays mixed signals. The stock now fluctuates between its 50-day moving average, set at 13.35 euros, and its Bollinger bands that frame volatility between 13.43 euros (lower limit) and 26.45 euros (upper limit). The 200-day moving average remains distant at 6.25 euros, creating a gap of more than 7 euros with the current price and reflecting the strong appreciation over the year. The Relative Strength Index is at 38, indicating a zone where selling movements dominate without reaching extreme oversold conditions. The MACD, a momentum component, shows a negative signal line at -1.31, suggesting a tempered bullish dynamic. Support and resistance levels are set between 8.49 euros and 24.45 euros, offering a broad framework for evolution and reflecting this characteristic volatility.
